Biomarkers

Cannabinoids, Dupuytren, and Orphan Drugs

I was recently asked if medical marijuana might be helpful for Dupuytren disease. The short answer is “No one knows.”. The longer answer is much more interesting. The late effect of Dupuytren disease is Dupuytren contracture. The medical term for the findings in Dupuytren contracture is fibrosis. Sclerosis also means the same thing. If either of […]

Read more ›
Happy Valentine’s Day from Dupuytren Research Group!
On: Feb 14, 2017
By: Charles Eaton

Two Dupuytren stories for this Valentine’s Day. First, Saint Valentine. There were nearly a dozen people called Saint Valentine. Did this one have Dupuytren Contracture? He’s clearly in the high risk demographic – an old Caucasian man. Looks like he’s got it, but we’ll never know. It is important to know that there’s a lot […]

Read more ›
The Future is Coming!

Improving the Future of Dupuytren Care Right now, many people with mild Dupuytren biology do well after surgery or after Xiaflex – because most people have mild to moderate Dupuytren biology. The issue isn’t the patient with mild disease biology who will do well for a long time after any treatment. The issue is those […]

Read more ›
Happy Thanksgiving from the Dupuytren Foundation!

Turkey Day Update! Much has happened since the last Dupuytren Foundation report in July. The International Dupuytren Data Bank (IDDB) averages 100 new enrollees each month. We’re continuing to work out the complicated details of blood testing. If you haven’t enrolled yet, now is the time: http://DupStudy.com. Our international research committee continues to grow. So does […]

Read more ›
Speeding up Dupuytren research

A hand surgery colleague just sent me hand pictures of a patient he had treated with needle aponeurotomy seven years ago. His patient recently had a recurrence and had an excellent outcome with repeat needle aponeurotomy. A great result, more impressive because things don’t always go as well. It’s an example of the ups and downs […]

Read more ›
Biomarkers in Dupuytren Disease
IDDB, biomarkers and big data to cure Dupuytren disease
On: Dec 9, 2015
By: Charles Eaton

The International Dupuytren Data Bank (IDDB) will focus on Dupuytren biomarkers Why are biomarkers important for Dupuytren disease? Dupuytren contracture is an effect, not a cause. Think of fever. Fever is an effect of infection, drug reaction, or something else. Just treating the effect – the fever – doesn’t cure the cause. ‌‌ You have to find […]

Read more ›